Olr1718 inhibitors belong to a specific category of chemical compounds that target the olfactory receptor Olr1718, a G-protein-coupled receptor (GPCR) involved in the detection and transduction of olfactory signals in mammals. This receptor, like other olfactory receptors, is integral to the complex process of olfaction, where chemical signals from the environment are converted into neural signals that can be interpreted by the brain. The inhibitors of Olr1718 are molecules that specifically bind to this receptor, effectively blocking its activity. By inhibiting Olr1718, these compounds can modulate the olfactory signaling pathways, which can lead to alterations in the perception of certain smells. The inhibition is typically achieved through competitive binding at the active site or through allosteric modulation, where the inhibitor binds to a different site on the receptor and induces conformational changes that reduce its activity.
The study of Olr1718 inhibitors is of particular interest in the field of chemical biology, where researchers aim to understand the specific roles of different olfactory receptors in sensory perception. These inhibitors are valuable tools for dissecting the molecular mechanisms underlying olfactory reception and for mapping the specific ligands that each receptor recognizes. By analyzing the structure-activity relationships (SAR) of these inhibitors, scientists can gain insights into the structural features necessary for receptor binding and inhibition. This information can further elucidate the broader functional roles of olfactory receptors, not only in olfaction but also in other physiological processes where these receptors may be involved. Additionally, the development of Olr1718 inhibitors involves extensive screening and optimization processes, where various chemical scaffolds are synthesized and tested to achieve high specificity and potency against the receptor.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
BCL-2 inhibitor, potentially affecting apoptotic pathways relevant to Olr1718. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
CDK4/6 inhibitor, could modulate cell cycle regulation pathways impacting Olr1718. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Multi-targeted receptor tyrosine kinase inhibitor, potentially disrupting several signaling pathways involving Olr1718. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Inhibits multiple tyrosine kinases, could affect pathways influencing Olr1718, like angiogenesis or cell proliferation. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
EGFR tyrosine kinase inhibitor, could disrupt signaling pathways that regulate Olr1718 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Multi-kinase inhibitor, potentially affecting angiogenesis and cell proliferation pathways relevant to Olr1718. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual EGFR and HER2 inhibitor, might modulate signaling pathways relevant to Olr1718's function. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
BCR-ABL kinase inhibitor, potentially influencing cell proliferation and survival pathways impacting Olr1718. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Src family kinase inhibitor, might alter cell proliferation and survival pathways affecting Olr1718. | ||||||